Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Jianjun Zou, Zhehai Wang et al.|The Lancet Respiratory Medicine|2020Cited by 504
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)Feng‐Hua Wang, Rui‐Hua Xu, Xiaoli Wei et al.|Journal of Clinical Oncology|2021Cited by 350
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialShengxiang Ren, Caicun Zhou, Jianhua Chen et al.|Journal of Thoracic Oncology|2021Cited by 311